BeiGene showcased strong performance in 2024

BeiGene recently released its financial performance for 2024, showing that its total annual revenue reached $3.8 billion, a 55 percent year-on-year increase.

The star product Zanubrutinib achieved global sales exceeding $2.6 billion, marking a 105 percent year-on-year growth and becoming the first domestic drug with annual sales exceeding 10 billion yuan ($1.38 billion).

In the US market, it achieved annual sales of $2 billion, establishing itself as a leader in treating chronic lymphocytic leukemia and other therapeutic areas.

Furthermore, BeiGene's self-developed product, the PD-1 Tislelizumab Injection, also saw steady growth with annual sales of $621 million, a 16 percent increase year-on-year. This was mainly due to the expansion of medical insurance coverage and an increase in the number of drug entries in hospitals.

BeiGene Biologics Guangzhou Manufacturing Facility. [Photo/WeChat account: guangzhougaoxinqu]

BeiGene has also made significant strides in globalization, with its Guangzhou biopharmaceutical production base becoming one of the key sites for large molecule production in Asia. Located in the Sino-Singapore Guangzhou Knowledge City, this production base is an essential strategic layout for BeiGene.

BeiGene expects to achieve positive operating profit and cash flow under US Generally Accepted Accounting Principles in 2025. The company plans to adopt a new name, BeOne, and a new stock code, ONC.

Share - WeChat